Table 3.

Fibronectin, Infiltrating Monocyte/Macrophages, and Myofibroblasts in WT vs. PAI-1−/− Mice at Day 5 after UUO

	Fibronectin positive area (%)		F4/80 positive area (%)		alpha-SMA positive area (%)
Treatment	WT	PAI-1−/−	WT	PAI-1−/−	WT	PAI-1−/−
Control	2.35±0.23	2.08±0.08	1.70±0.11	1.30±0.07†	2.64±0.56	2.27±0.27
POPi	2.05±0.13	2.17±0.28	1.59±0.03	1.37±0.16	1.86±0.25	2.20±0.08
Tβ4+POPi	3.20±0.32*	2.06±0.07†	1.55±0.07	1.22±0.17	2.82±0.20	2.03±0.13†
Tβ4	2.32±0.26	1.69±0.27	1.86±0.07	1.12±0.06	1.73±0.13	1.86±0.21
Ac-SDKP	1.41±0.15*	1.36±0.15*	0.83±0.09*	1.06±0.07 *,†	0.92±0.05*	1.59±0.18*, †

Abbreviations: POPi, POP inhibitor; Tβ4+POPi, thymosin β4 plus POP inhibitor; Tβ4, thymosin β4

Data are given as percentage of immunostaining positive area, mean ± SEM, n=5–8 in each group.

^*p<0.05 vs. its own control

^†p<0.05 for WT vs. PAI-1−/− mice with same treatment.